Essential Partners
TVTX icon

Essential Partners’s Travere Therapeutics TVTX Stock Holding History

Essential Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.48K Sell
93
-202
-68% -$12.3K ﹤0.01% 1465
2026
Q2 		$16.8K Sell
295
-98
-25% -$4.34K 0.01% 974
2026
Q1 		$11.7K Hold
393
– – ﹤0.01% 1175
2025
Q4 		$15K Buy
393
+112
+40% +$3.64K ﹤0.01% 1011
2025
Q3 		$6.72K Sell
281
-396
-58% -$7.44K ﹤0.01% 1306
2025
Q2 		$10K Buy
+677
New +$11.2K ﹤0.01% 847

Other funds holding TVTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Insight Wealth Strategies
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
OpenArc Corporate Advisory
OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
Burney Company
Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Essential Partners's TVTX Position: Q3 2026 in Review

Essential Partners reduced its Travere Therapeutics (TVTX) stake by 68% in Q3 2026, selling an estimated $12.3K and leaving 93 shares worth $5.48K. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

Essential Partners first reported a position in TVTX in Q2 2025 and has held it in 6 quarters since. The position peaked at $16.8K in Q2 2026. 35 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • Essential Partners held 93 shares of Travere Therapeutics worth $5.48K as of Q3 2026.
  • Essential Partners sold 202 Travere Therapeutics shares in Q3 2026, an estimated $12.3K.
  • Travere Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1465 holding.
  • Essential Partners first reported a position in Travere Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Travere Therapeutics position peaked at $16.8K in Q2 2026.
  • 35 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.